Allogene Therapeutics, Inc. (ALLO) Stock Forecast
ALLO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.58 / 5 from 12 analysts
- Price target
- $9.00 average of analyst targets
- Upside to target
- +587.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.13
- 52-week range
- $1.05 – $3.06
ALLO analyst ratings
12 analystsNumber of analysts at each rating.
ALLO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ALLO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.18 | −$0.09 | −$0.19 | +25.9% | 7 |
| Current fiscal year (2026) | −$0.59 | −$0.68 | −$0.38 | −$0.85 | +31.4% | 7 |
| Next fiscal year (2027) | −$0.62 | −$0.93 | −$0.40 | −$0.59 | −5.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ALLO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2,000 | $0 | $20,000 | 0.0% | 10 |
| Current fiscal year (2026) | $3.4M | $0 | $5.0M | 0.0% | 11 |
| Next fiscal year (2027) | $12.1M | $0 | $63.0M | +255.5% | 10 |
ALLO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ALLO revenue: reported and forecast
ALLO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −$0.14 | −0.9% | 2 up · 1 down |
| Current fiscal year (2026) | −$0.61 | −$0.61 | −$0.59 | −$0.59 | −$0.59 | −3.6% | 2 up · 0 down |
| Next fiscal year (2027) | −$0.68 | −$0.68 | −$0.65 | −$0.65 | −$0.62 | −9.8% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ALLO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ALLO beat in 12 of 12.
What analysts expect from ALLO
12 analysts cover Allogene Therapeutics; their consensus rating is strong buy (4.58 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.00, 587.0% above the latest close of $1.31. Analysts expect earnings of −$0.59 per share for 2026, +31.4% from a year earlier. For 2027 the average estimate is −$0.62 per share on revenue of $12.1 million. Allogene Therapeutics beat the EPS estimate in 12 of the last 12 quarters.
Related: ALLO income statement, ALLO key metrics, ALLO chart. See the ALLO stock overview for the latest quote and news.
ALLO forecast FAQ
What is Allogene Therapeutics's price target?
The average analyst price target for Allogene Therapeutics is $9.00, 587.0% above the latest close of $1.31.
Is Allogene Therapeutics a buy, hold or sell?
Of 12 analysts covering Allogene Therapeutics, 8 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Allogene Therapeutics's EPS forecast?
Analysts forecast −$0.59 per share for 2026 (range −$0.68 to −$0.38); for 2027 the estimate is −$0.62.
What is Allogene Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $3.4 million, growth of 0.0%; for 2027 it is $12.1 million.
When does Allogene Therapeutics report earnings?
Allogene Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.13.
Does Allogene Therapeutics usually beat earnings estimates?
Allogene Therapeutics reported EPS at or above the analyst estimate in 12 of the last 12 quarters.